Accretive Wealth Partners LLC Has $2.42 Million Position in Johnson & Johnson $JNJ

Accretive Wealth Partners LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.1% during the 2nd quarter, HoldingsChannel reports. The firm owned 15,859 shares of the company’s stock after purchasing an additional 171 shares during the quarter. Accretive Wealth Partners LLC’s holdings in Johnson & Johnson were worth $2,423,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Ellis Investment Partners LLC lifted its position in Johnson & Johnson by 0.7% in the second quarter. Ellis Investment Partners LLC now owns 8,559 shares of the company’s stock worth $1,307,000 after purchasing an additional 62 shares during the period. Cypress Wealth Services LLC increased its stake in shares of Johnson & Johnson by 0.9% in the second quarter. Cypress Wealth Services LLC now owns 6,634 shares of the company’s stock valued at $1,013,000 after buying an additional 62 shares in the last quarter. Horizon Bancorp Inc. IN increased its position in Johnson & Johnson by 11.2% in the second quarter. Horizon Bancorp Inc. IN now owns 636 shares of the company’s stock worth $97,000 after purchasing an additional 64 shares during the period. Global Strategic Investment Solutions LLC increased its position in Johnson & Johnson by 3.5% in the second quarter. Global Strategic Investment Solutions LLC now owns 1,925 shares of the company’s stock worth $294,000 after purchasing an additional 65 shares during the period. Finally, JSF Financial LLC grew its position in shares of Johnson & Johnson by 2.2% during the 2nd quarter. JSF Financial LLC now owns 2,993 shares of the company’s stock worth $457,000 after buying an additional 65 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on JNJ shares. Guggenheim upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Raymond James Financial lifted their price objective on Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a report on Wednesday, October 15th. Morgan Stanley set a $190.00 target price on Johnson & Johnson in a research note on Wednesday, October 15th. Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Finally, Wells Fargo & Company set a $212.00 target price on Johnson & Johnson and gave the company an “overweight” rating in a research note on Friday, October 3rd. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $200.06.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $193.78 on Tuesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.48. The company has a market cap of $466.68 billion, a price-to-earnings ratio of 18.70, a PEG ratio of 2.27 and a beta of 0.40. The stock has a fifty day moving average price of $180.89 and a 200-day moving average price of $165.18.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Insider Activity

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.16% of the stock is owned by company insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.